Wednesday, January 8, 2020

Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall "We understand from Mylan NV#39;s press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to detected trace amounts of impurity...," Solara Active Pharma Sciences in a filing to BSE.

from Moneycontrol Business News https://ift.tt/36B1RCp
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Good news for Indian mutual fund investors: SpaceX could join Nasdaq 100 after 15 trading days

SpaceX’s expected entry into the Nasdaq-100 could give Indian investors indirect exposure through Nasdaq-linked mutual funds. Jefferies says...